cDNA arrays were used to examine gene induction in CALU-6 and H460 lung cancer cells mediated by sequential 5-aza 2 0 -deoxycytidine (DAC)/depsipeptide FK228 (DP) exposure in order to identify translational end points for clinical trials evaluating these agents. In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduction known to diminish the malignant phenotype of cancer cells. TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies. Sequential DAC/DP treatment induced TFPI-2 in cancer cells deficient for TFPI-2 expression in the basal state. Promoter methylation coincided with loss of TFPI-2 expression in a number of cancer lines. TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues. DP enhanced acetylation of TFPI-2-associated histones in CALU-6 cells. DP or PDBU, alone, induced TFPI-2 expression in cancer cells deficient for TFPI-2 expression in the absence of promoter methylation. In these cells, DP-mediated TFPI-2 induction was abrogated by calphostin. Induction of TFPI-2 by distinct, yet cooperative mechanisms involving chromatin remodeling and PKC signaling strengthens the preclinical rationale for sequential administration of DNA demethylating agents and HDAC inhibitors in cancer patients. Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions.
Introduction
Dynamic patterns of gene expression during proliferation, differentiation, and apoptosis in normal and malignant cells are mediated in part via epigenetic mechanisms involving DNA methylation and histone acetylation (Wade, 2001; Jones and Baylin, 2002) . In mammalian cells, the opposing actions of DNA methyltransferases (DNMTs) and DNA demethylases regulate methylation of cytosines within CG dinucleotides (Robertson, 2001) . Methylation of CpG islands within promoter and proximal coding regions inhibits binding of transcription factors, and facilitates recruitment of methyl cytosine binding proteins such as MeCP2 and MBD2, which associate with other proteins including sin3a, Rb, and histone deacetylases (HDACs) to inhibit initiation (Robertson, 2001; Attwood et al., 2002) . Limited information is available concerning DNA demethylation that occurs either passively during DNA replication, or actively via mechanisms involving proteins such as 5-methylcytosine DNA glycosylase (5-MCDG), which catalyses nucleotide excision repair of 5-methyldeoxycytidine independent of DNA replication (Detich et al., 2003; Vairapandi, 2004) .
Recent studies indicate that DNA methylation is the predominant epigenetic mechanism regulating gene expression, and that DNA methylation is mechanistically linked to histone acetylation (Rea et al., 2000; Fahrner et al., 2002) . In general, hypermethylated promoters are associated with nucleosomes containing hypoacetylated core histones (Wade, 2001) . Acetylation of core histones is governed, in part, by the opposing actions of histone acetyltransferases (HATs) such as PCAF, GCN-5, p300/CBP, and TAF-250, and a variety of histone deacetylases, each of which exhibit highly restricted protein and DNA substrate specificities (Kouzarides, 1999) . Extracellular regulated protein kinases (ERK1/2) mediate the activation and localization of several HDACs (Zhou et al., 2000) . Although it has been well established that DNA methylation promotes histone deacetylation and inhibition of transcription in normal and malignant cells, recent studies indicate that active chromatin facilitates DNA demethylation via demethylase mechanisms directed by histone acetylation (Cervoni and Szyf, 2001) .
The emerging relationships between cell cycle regulation, epigenetics, and cancer have prompted considerable research efforts focused on the evaluation of agents that modulate chromatin structure for cancer therapy (Santini et al., 2001; Vigushin and Coombes, 2002) . The DNA demethylating agent 5-aza 2 0 -deoxycytidine (DAC) has been studied extensively as a cytotoxic and differentation agent in hematologic malignancies as well as solid tumors (reviewed by Santini et al., 2001) . Whereas the antineoplastic effects of this agent may be related to restoration of tumor suppressor gene expression (Bender et al., 1998; Daskalakis et al., 2002 ), the precise mechanisms by which DAC inhibits cancer growth in vivo have not been fully defined; indeed, cytotoxicity mediated by DAC appears related primarily to covalent trapping of DNMT on DNA, rather than DNA demethylation per se (Juttermann et al., 1994) .
HDAC inhibitors such as depsipeptide FK228 (DP) mediate growth arrest, differentation and apoptosis in cancer cells in vitro and in vivo . Whereas the cytotoxic effects of HDAC inhibitors have been ascribed to alterations in chromatin structure, recent data indicate that histone acetylation is insufficient to account for the antiproliferative effects of these agents in tumor cells (Brinkmann et al., 2001) . Induction of p21 expression, inhibition of cdk2 kinase activity, and depletion of a variety of oncoproteins by mechanisms unrelated to modulation of chromatin structure contribute significantly to the cytotoxic effects of HDAC inhibitors in cancer cells (Kim et al., 2000; Sandor et al., 2000; Yu et al., 2002) .
Previously, Cameron et al. (1999) observed that HDAC inhibitors potentiate tumor suppressor gene induction mediated by DNA demethylating agents in cancer cells. Shortly thereafter, we reported that under clinically achievable conditions, DP markedly potentiates DAC-mediated tumor antigen expression, growth arrest, and apoptosis in lung and esophageal cancer cells, as well as malignant pleural mesothelioma cells, but not cultured normal human bronchial epithelia (Weiser et al., 2001a, b) . Subsequently, Zhu et al. (2001) confirmed that FK228 enhanced DAC-mediated cytotoxicity in lung cancer cells. Collectively, these observations have provided compelling preclinical rationale for the evaluation of DNA demethylating agents in conjunction with HDAC inhibitors in cancer patients. Identification of surrogate molecular end points, which could confirm threshold drug exposure in tumor tissues and enable validation of molecular mechanisms associated with clinical response might facilitate the development of cancer therapies utilizing chromatin remodeling agents. The present study was undertaken to identify potentially relevant genes induced by sequential DAC/DP exposure that might serve as appropriate translational endpoints in clinical trials evaluating DNA demethylating agents and HDAC inhibitors in patients with thoracic malignancies.
Results
Induction of TFPI-2 in CALU-6 and H460 cells cDNA microarray experiments were performed using mRNA isolated from CALU-6 and H460 lung cancer cells exposed to normal media (NM) or sequential DAC/DP in order to identify potential translational end points for analysis in primary thoracic malignancies following exposure to these agents. These cell lines were chosen for study because they exemplified effects of DAC and DP typically observed in our cultured cell line panel (Figure 1 ), and exhibited k-ras mutations but different p53, p16, and p14/ARF genotypes (Lehman et al., 1991; Mukhopadhyay et al., 1991; Shapiro et al., 1995; Sato et al., 2002) . Expression levels of approximately 9% of the genes on the arrays were modulated two fold or more by sequential DAC/DP treatment (data not shown). Interestingly, sequential DAC/DP exposure mediated pronounced induction of tissue factor pathway inhibitor two (TFPI-2) in CALU-6 and H460 cells, respectively, (representative data pertaining to CALU-6 cells depicted in Figure 2 ).
Since recent studies have indicated that TFPI-2 inhibits the malignant phenotype of cancer cells in vitro and in vivo (Jin et al., 2001; Konduri et al., 2001a; Rao et al., 2001) , additional experiments were undertaken to confirm the results of the cDNA arrays. Reverse transcriptasepolymerase chain reaction (RT-PCR) analysis revealed induction of TFPI-2 expression in CALU-6 cells following DAC exposure (0.1 mM Â 72 h). Depsipeptide alone (25 ng/ml Â 6 h) alone did not appear to induce TFPI-2 expression; however, this HDAC inhibitor augmented DAC-mediated induction of this target gene (Figure 3a) . Northern analysis demonstrated that DAC enhanced steady-state TFPI-2 mRNA levels, and that DP increased steady-state levels of TFPI-2 transcripts induced by DAC in CALU-6 cells ( Figure 3a) . Immunohistochemistry (IHC) experiments confirmed that DAC-but not DP alone, induced low-level TFPI-2 protein expression in CALU-6 cells, and that sequential DAC/DP treatment markedly enhanced TFPI-2 protein expression in these lung cancer cells (Figure 3b ).
Analysis of TFPI-2 expression in cultured lung and esophageal cancer and pleural mesothelioma cells
In light of the fact that TFPI-2 was silenced in CALU-6 cells, additional experiments were performed to examine TFPI-2 expression in a broad panel of cultured cell lines derived from thoracic malignancies. RT-PCR analysis indicated that TFPI-2 expression was markedly diminished in 16 of 32 cell lines established from lung and esophageal carcinomas, or malignant pleural mesotheliomas (Figure 4a ). Of note was the apparent loss of TFPI-2 expression in the majority of esophageal carcinoma lines. IHC experiments confirmed the results of RT-PCR analysis of TFPI-2 expression in cultured cancer cells (data pertaining to 12 representative cell lines depicted in Figure 4b ). The patterns of immunoreactivity varied somewhat between cell lines TFPI-2 induction in cancer cells FA Steiner et al exhibiting TFPI-2 expression by RT-PCR, ranging from very strong pancellular, intracytoplasmic and peri-membranous staining such as that seen in H460 cells, to less intense cytoplasmic staining such as that observed in A549 cells. Several cell lines including H596, SK-LU-1, and H290, which appeared to have somewhat less pronounced TFPI-2 expression on the basis of RT-PCR analysis exhibited more focal TFPI-2 immunoreactivity. Overall, the patterns of TFPI-2 immunoreactivity in cultured cells were consistent with recently published data pertaining to the immunohistochemical analysis of TFPI-2 expression in human cancer xenografts in mice, as well as normal tissues and primary cancers in humans, in which cytoplasmic and perimembranous staining presumably detected TFPI-2, which had not yet been secreted into the extracellular matrix (Wojtukiewicz et al., 2003; Chand et al., 2004) .
Since sequential DAC/DP treatment mediated induction of TFPI-2 in CALU-6 cells, additional studies were performed to determine if similar drug treatment could induce TFPI-2 expression in other cultured cancer cells that did not express this target gene. Quantitative RT-PCR experiments revealed that sequential DAC/DP treatment mediated pronounced induction of TFPI-2 in virtually all of the cancer lines in which this gene was not expressed in the basal state; interestingly, several patterns of TFPI-2 induction were observed (representative data depicted in Table 1 ). The first pattern was typified by CALU-6 cells, in which TFPI-2 was induced by DAC but not DP, and the induction mediated by sequential DAC/DP treatment markedly exceeded that observed following exposure to either agent alone. A second pattern of TFPI-2 induction was exemplified by H28 cells in which expression of this target gene was mediated primarily by DP; whereas DAC had minimal effect, sequential DAC/DP treatment always induced more TFPI-2 expression than DP alone. A third pattern of induction was exemplified by H1184 cells in which DAC and DP treatments alone enhanced TFPI-2 expression; once again, the effects of sequential DAC/ DP were supra-additive in these cells. Although actual mRNA copy numbers varied somewhat, the trends observed for each cell line were quite reproducible in three independent experiments. Interestingly, sequential DAC/DP treatment enhanced TFPI-2 expression in H460 cells which expressed TFPI-2 in the basal state; Figure 1 Proliferation of CALU-6 and H460 cells exposed to NM, DAC, DP, and DAC/DP assessed by trypan blue exclusion techniques. Cells were exposed to NM; DAC (0.1 mM Â 72 h), followed by NM; NM Â 72 h, then DP(25 ng/ml Â 6 h), followed by NM; or DAC (0.1 mM Â 72 h) followed by DP (25 ng/ml Â 6 h), then NM. Mean and s.d. of triplicate counts; *Po0.05 relative to NM; **Po0.05 relative to DAC or DP Figure 2 Representative scatterplot of cDNA array of gene expression in CALU-6 cells exposed to sequential DAC/DP relative to untreated CALU-6 cells. Exposure conditions were identical to those described in Figure 1 . The point corresponding to TFPI-2 is depicted in the rectangle. The fold induction of TFPI-2 mediated by DAC/DP in CALU-6 cells ranged between 13 and 21 in three independent arrays
TFPI-2 induction in cancer cells
FA Steiner et al the magnitude of induction of TFPI-2 expression in these cells (as well as CALU-6 cells) detected by quantitative RT-PCR techniques was consistent with preliminary data derived from the cDNA array experiments.
Regulation of TFPI-2 expression in cancer cells
Induction of TFPI-2 by sequential DAC/DP treatment suggested that expression of this target gene was regulated (at least in part) by chromatin structure. A 275 bp region that fulfilled criteria for CpG island was identified in the 3 0 end of the TFPI-2 promoter; methylation-specific PCR (MSP) experiments were performed to evaluate this CpG island in cultured cancer cells. As shown in Figure 5 , this analysis indicated that the TFPI-2 promoter was methylated in CALU-6 cells, and unmethylated in H460 cells -results that were consistent with quantitative RT-PCR data discussed previously. Numerous other cell lines (including H889 lung cancer cells, as well as TE-12 and SKGT-5 esophageal cancer cells) that were deficient for TFPI-2 expression exhibited methylation of the TFPI-2 promoter. PCR products corresponding to unmethylated TFPI-2 templates were observed in H889 and TE-12 cells suggesting that the region recognized by the MSP primers was not fully methylated in all of the cells from these cancer lines. Nevertheless, the presence of a PCR product corresponding to a methylated TFPI-2 promoter sequence was associated with loss of TFPI-2 expression in these cells. In contrast, the absence of a 'methylated' PCR product did not always coincide with retention of TFPI-2 expression in cancer cells. For instance, MSP experiments suggested that the TFPI-2 promoter was not methylated in H28 and H526 cells, which were deficient for TFPI-2 expression by RT-PCR and IHC analysis (Figure 4a and b). Whereas these observations did not exclude the possibility of potentially relevant methylation adjacent to the region examined by MSP, the data suggested that promoter methylation status alone was insufficient to account for silencing of TFPI-2 expression in cultured cancer cells.
Bisulfite sequencing experiments were next undertaken to further examine TFPI-2 promoter methylation in cultured cancer cells. This analysis revealed considerable methylation of the 29 CG dinucleotides within the CpG island of the TFPI-2 promoter in CALU-6 cells ( Figure 6 ). H446 SCLC, as well as TE-12 and TE-13 EsC cells also exhibited methylation of this CpG island, albeit to a slightly lesser extent than CALU-6 cells. Significant demethylation of the CpG island was noted in CALU-6 cells following DAC exposure. The TFPI-2 promoter was unmethylated in H460 and NHBE cells ( Figure 6 ). Interestingly, bisulfite sequencing analysis also demonstrated that the TFPI-2 promoter was unmethylated in H28 MPM and H526 SCLC cells which were also deficient for TFPI-2 expression in the basal state (data pertaining to H28 cells depicted in Figure 6 ). Overall, the results of the bisulfite sequencing experiments were consistent with those obtained by MSP.
Having verified the MSP results in cultured cells, we next examined TFPI-2 promoter methylation status in primary thoracic malignancies. MSP analysis revealed methylation of the TFPI-2 promoter in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas but not corresponding normal tissues (data summarized in Table 2 ). In one surgical specimen containing adenocarcinoma as well as Barrett's mucosa and normal epithelium, TFPI-2 promoter methylation was observed in the cancer as well as the Barrett's mucosa, but not normal epithelial cells. Results of this preliminary analysis were consistent with data from cultured cancer cells, and indicated that TFPI-2 promoter methylation may be a clinically relevant molecular event in thoracic malignancies.
Having observed that promoter hypermethylation contributed to silencing of TFPI-2 expression in cancer cells, we next sought to determine the mechanisms by which DP mediates its effects on the TFPI-2 promoter.
Figure 3 (A) Analysis of TFPI-2 expression in CALU-6 cells exposed to NM, DAC, DP, or sequential DAC/DP assessed by RT-PCR, and Northern blot techniques. CALU-6 cells were exposed to NM, DAC, DP, or sequential DAC/DP as described in the Materials and methods section and summarized in Figure 1 . RT-PCR and Northern analysis of TFPI-2 expression were performed 96 h after the start of treatment for all conditions. D/D5: sequential DAC (0.1 mM Â 72 h)/DP (5 ng/ml Â 6 h); D/D25: sequential DAC (0.1 mM Â 72 h)/DP (25 ng/ml Â 6 h). (B) IHC analysis of TFPI-2 expression in CALU-6 cells exposed to NM (panel a), DAC (panel b), DP (panel c), or sequential DAC/DP (panel d). Exposure conditions were identical to those described in the Materials and methods section; analysis of TFPI-2 protein expression was performed at the 96-h time point for all exposure conditions TFPI-2 induction in cancer cells FA Steiner et al Preliminary Western blot analysis confirmed that when administered at the dose used for the induction experiments, DP mediated acetylation of histones H3 and H4 (data not shown). Subsequent chromatin immunoprecipitation (ChIP) experiments clearly demonstrated enhanced acetylation of histone H3 associated within the CpG island of the TFPI-2 promoter (Figure 7) . Under similar conditions, enhanced acetylation of histone H4 was also observed following DP treatment. Collectively, these data confirmed that DP modulates chromatin structure within the CpG island of the TFPI-2 promoter.
Since DP as well as apicidin induce p21 expression via PKC signal pathways (Han et al., 2001; Nguyen et al., 2004) , additional experiments were performed to ascertain if DP augmented TFPI-2 expression via similar Representative results of IHC analysis of TFPI-2 expression in untreated cancer cell lines. Panels a-h: H460, CALU-6, H596, A549, H358, SK-Lu-1, H417, and H526 lung cancer cell lines, respectively. Panels i and j: TE-12 and TE13 esophageal cancer lines, respectively; panels k and l: REN and H290 MPM cell lines, respectively. Cell lines depicted in (A) were pelleted in a thrombin-fibrin clot, fixed in formalin, and embedded in parafin as described in the Materials and methods section. TFPI-2 expression in the pelleted cells was detected by immunoperoxidase techniques using a sepharose A-purified rabbit polyclonal antisera recognizing TFPI-2. Overall, the results of the IHC analysis were consistent with data from the RT-PCR experiments, indicating loss of TFPI-2 expression in approximately 50% of cultured lung and esophageal cancer, and MPM cell lines
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RT-PCR analysis revealed that the PKC agonist, PDBU alone did not induce TFPI-2 expression in CALU-6 cells exhibiting TFPI-2 promoter methylation; however, PDBU clearly augmented TFPI-2 expression in these cells following DAC treatment (Figure 8 ). PDBU alone was sufficient to induce TFPI-2 expression in H28 cells, which were deficient for TFPI-2 expression in the absence of promoter hypermethylation. Sequential DAC/PDBU treatment did not appear to significantly increase TFPI-2 expression relative to that mediated by PDBU treatment alone in H28 cells; these results were consistent with those observed following treatment of H28 cells with sequential DAC/ DP (Table 1) . Abrogation of DAC/DP-mediated induction of TFPI-2 expression in CALU-6 cells by the PKC antagonist, calphostin C, could not be assessed due to the toxicity of this treatment regimen. However, DP-or PDBU-mediated induction of TFPI-2 expression in H28 cells was clearly inhibited by calphostin. Collectively, these data suggested that modulation of PKC signal transduction contributes to DP-mediated induction of TFPI-2 expression in cancer cells.
Discussion
Due to their novel mechanisms of action and preferential cytotoxicity in transformed cells, DNA demethylating Figure 5 MSP analysis of the TFPI-2 promoter in CALU-6, H460, H889, and H526 lung cancer cells, TE-12 and SKGT-5 esophageal cancer cells, and H-28 mesothelioma cells. A 'methylated' PCR product always coincided with loss of TFPI-2 expression in cancer cells; however, the absence of a 'methylated' PCR product did not always indicate retained expression of TFPI-2, suggesting that promoter methylation is not the sole mechanism by which TFPI-2 is silenced in thoracic malignancies Figure 6 Results of bisulfite sequencing analysis of the CpG island within the TFPI-2 promoter in CALU-6 cells exposed to NM or DAC (0.l mM Â 72 h), as well as untreated TE-12, TE-13, H446, and H28 cancer cells, and NHBE cells. The TFPI-2 promoter was unmethylated in H460 as well as H526 cells (data not shown). The results of this analysis confirmed the MSP experiments TFPI-2 induction in cancer cells FA Steiner et al agents and HDAC inhibitors have emerged as promising compounds for cancer therapy. In the present study, we sought to identify clinically relevant molecular end points, which could be utilized to assess treatment response in target tissues from thoracic oncology patients receiving sequential DAC/DP infusions. Using cDNA arrays we initially observed induction of TFPI-2 in CALU-6 as well as H460 lung cancer cells. Owing to the paucity of data concerning TFPI-2 expression in thoracic malignancies, we performed additional experiments, which revealed that TFPI-2 expression was diminished in approximately 50% of cell lines derived from thoracic malignancies, and that TFPI-2 expression could be induced in these cell lines by sequential DAC/ DP treatment. To the best of our knowledge, this is the first report to document loss of TFPI-2 expression in thoracic malignancies, and induction of TFPI-2 expression in cultured cells derived from these neoplasms following sequential exposure to DNA demethylating agents and HDAC inhibitors. Initially identified as placental protein 5 (PP5), TFPI-2 is a 32 kDa Kunitz-type serine protease inhibitor, which exhibits homology with TFPI-1, a major regulator of the extrinsic coagulation pathway (Sprecher et al., 1994; Rao et al., 1996) . TFPI-2 inhibits trypsin, chymotrypsin, plasmin, and plasma kallikrein, as well as Factor XIa, and Factor VII : tissue factor complex (Sprecher et al., 1994) . TFPI-2 is normally expressed and secreted by a variety of cells including endothelia, fibroblasts, myocytes, keratinocytes, and syncytiotrophoblasts . Approximately 70-90% of TFPI-2 is associated with the extracellular matrix (ECM) (Rao et al., 1996) . Whereas TFPI-2 is known to associate with heparin and dermatan sulfate (Liu et al., 1999) , the components of the ECM that interact with this protein inhibitor have not been fully defined.
Although the role of TFPI-2 in regulating homeostasis in normal and malignant cells remains unclear, several recent studies suggest that this protein may modulate the malignant phenotype of cancer cells in vitro and in vivo. Angiogenic and metastatic potential of cancer cells frequently coincides with tissue factor (TF) expression, and TF-dependent metastasis requires catalytically active Factor VII (Mueller et al., 1992; Folkman, 1996; Mueller and Ruf, 1998; Bromberg et al., 1999) . Binding of Factor VII to TF enhances signal transduction via p44/42, src, and p38 pathways in cultured fibroblasts, baby hamster kidney cells, and smooth muscle cells (Poulsen et al., 1998; Abe et al., 
T: tumor; Nl: normal mucosa; B: Barrett's mucosa; M: methylated; U: unmethylated Figure 7 ChIP analysis of the CpG island of the TFPI-2 promoter from CALU-6 cells before and after DP treatment. CALU-6 cells were exposed to NM, or DP (25 ng/ml) for either 6 or 24 h. ChIP analysis was performed at the 24-h time point for all exposure conditions. A time-dependent increase in PCR products in precipitated chromatin reflects increased acetylation status of histone H3 as well as histone H4 within the CpG island of the TFPI-2 promoter Figure 8 RT-PCR analysis of TFPI-2 expression in CALU-6 and H-28 cells following exposure to NM, DAC, DP, or DAC/DP, in the absence or presence of PDBU or calphostin C. Whereas PDBU was insufficient to induce TFPI-2 expression in CALU-6 cells, this PKC agonist clearly augmented DAC-mediated induction of this gene in these cancer cells. In contrast, PDBU alone was sufficient to induce TFPI-2 expression in H28 MPM cells, which are deficient for TFPI-2 expression in the absence of promoter hypermentylation. The PKC antagonist, calphostin C inhibits the effects of DP or PDBU, strongly suggesting that DP mediates its effects on TFPI-2 expression in part, via modulation of PKC signaling (Sprecher et al., 1994) , it is possible that the effects of TFPI-2 on Factor VII : tissue factor signaling in cancer cells may be rather modest, particularly in cells exhibiting other mutational events that constitutively activate MAP kinase signal transduction. Nevertheless, recent studies indicate that TFPI-2 is a transformation suppressor in v-K-rastransformed cells (Izumi et al., 2000) . TFPI-2 expression correlates in an inverse manner with histologic grade of primary human gliomas , and restoration of TFPI-2 expression decreases ERKmediated signal transduction, and enhances apoptosis in cultured glioma cells (Tasiou et al., 2001) . TFPI-2 inhibits invasion of ras-transformed NIH-3T3 cells, as well as human melanoma and prostate cancer cells in vitro (Konduri et al., , 2001b . Additional studies have shown that TFPI-2 inhibits several matrix metalloproteinases implicated in cancer metastasis (Rao et al., 1998 Herman et al., 2001; Baker et al., 2002) . Furthermore, TFPI-2 inhibits Factor VII : tissue factormediated expression of the proangiogenic ligand, interleukin 8 by cancer cells (Hjortoe et al., 2004) . TFPI-2 inhibits growth and metastasis of human glioma and fibrosarcoma xenografts in nude mice (Konduri et al., 2001a; Chand et al., 2004) . Whereas the role of TFPI-2 in thoracic malignancies has not been systematically evaluated, Lakka et al. (2000) observed that antisense to TFPI-2 enhances migration and invasiveness of A549 lung cancer cells in vitro. Although these observations suggest that TFPI-2 inhibits the malignant phenotype of cancer cells of diverse histologies, recent experiments by Neaud et al. (2000) as well as Shinoda et al. (1999) have shown that TFPI-2 is a potent mitogen for hepatocarcinoma as well as vascular smooth muscle cells. Collectively, these data indicate that the effects of TFPI-2 in cancer cells may be highly complex, and tissue specific. Until recently, limited information has been available concerning regulation of TFPI-2 expression in normal and malignant cells. The human TFPI-2 gene consists of five exons and four introns spanning approximately 7 kb; the nucleotide sequence of the human TFPI-2 gene is essentially identical to murine TFPI-2 gene (Kazama et al., 2000; Kamei et al., 2001a) . The TFPI-2 promoter lacks a TATA box; however, two CAAT boxes are located approximately 3 kb proximal to the transcription initiation site. Konduri et al. (2002) reported that region À312 to þ 1 of the TFPI-2 promoter was critical for basal as well as PMA-induced expression of this gene in glioma cells; region À312 to À81, which contains several positive regulatory sequences including AP-1, SP-1, NFkB, NFkB-like, and Lyf-1 binding sites appears essential for TFPI-2 transcription in these cells. In a subsequent study, Konduri et al. (2003b) observed that PMA, DAG, IFNa, and IFNg induced TFPI-2 expression in low-grade glioma cells, and that mutations involving two AP-1 or two SP-1 sites (À310 to À300 and À165 to À154, respectively), abrogated TFPI-2 promoter activation by these agents. On the other hand, mutations involving the third AP-1 site (À213 to À204), or nearby NFkB-like and Lyf-1 sites, had no impact on TFPI-2 promoter activation by these agents. More recently, Kast et al. (2003) reported that the MEK inhibitor U0126 abrogated PMA-mediated induction of TFPI-2 expression in cancer cells, and that TFPI-2 expression is regulated by the ras/raf/mek/erk pathway via one of the AP-1 sites identified by Konduri et al. (2003b) as critical for PMA-mediated induction of this target gene.
In addition to regulation by oncogene pathways and early response gene products, TFPI-2 expression appears to be governed by epigenetic mechanisms as well. MSP and bisulfite sequencing experiments described in this report clearly indicate that promoter methylation contributes to silencing of TFPI-2 expression in at least a subset of thoracic malignancies. In cell lines exhibiting TFPI-2 promoter methylation, TFPI-2 expression can be induced by DAC. These results are consistent with recent data by Rao et al. (2003) demonstrating methylation of the TFPI-2 promoter in HT1080 fibrosarcoma, MCF-7 breast cancer, and LnCa prostate cancer lines, and restoration of TFPI-2 expression in these cultured cells following exposure to 5-azacytidine. Markl et al. (2001) and Ueki et al. (2002) reported that methylation patterns in cultured cancer cells reflect those exhibited in the respective primary tumor specimens; our observations regarding the frequency of TFPI-2 promoter methylation in primary lung and esophageal adenocarcinomas relative to the loss of TFPI-2 expression in cultured cancer cells are consistent with these data. It is reasonable to speculate that based on our cell line data, TFPI-2 promoter hypermethylation will be observed in primary SCLCs, which are known to aberrantly express Factor VII, and exhibit procoagulant activity (Zacharski et al., 1987) . Overall, these observations suggest that promoter methylation may be a common mechanism contributing to inactivation of TFPI-2 in human cancers of diverse histologies. Comprehensive evaluation of TFPI-2 promoter methylation in primary thoracic malignancies is a focus of ongoing investigation in our laboratory.
While this manuscript was under initial review, Konduri et al. (2003a) , reported that TFPI-2 expression could be restored in SNB19 glioma cells by treatment with DAC (5 mM Â 3 days), and that trichostatin A (500 nM Â 20 h) could potentiate DAC-mediated induction of TFPI-2 in these cells. Data presented in this manuscript confirm and extend those of Konduri et al. (2003a) using clinically relevant drug exposure conditions. Recent data from our clinical trials indicate that steady-state DAC plasma concentrations approximated 30-50 nM when this DNA demethylating agent was administered by 72 h continuous intravenous infusion in TFPI-2 induction in cancer cells FA Steiner et al thoracic oncology patients (Schrump et al., manuscript submitted for publication). Hence, DAC plasma concentrations achieved in patients were at least 100-fold lower than those used by Konduri et al. (2003a) for their in vitro experiments. Furthermore, free DP concentrations in plasma of lung cancer patients approximated 25-50 ng/ml over 6 h following 4 h infusion of this HDAC inhibitor at the MTD (Schrump et al., manuscript submitted for publication), closely corresponding to the DP exposure conditions used for our in vitro studies. As DP is equipotent to TSA regarding HDAC inhibitory activity (Nakajima et al., 1998) , the exposure conditions for our studies were considerably lower than those used by Konduri et al. (2003a) . Interestingly, several patients receiving DAC or DP have exhibited induction of TFPI-2 in primary tumor tissues (DSSunpublished data), attesting to the potential clinical relevance of our in vitro data.
Several investigators have observed that TFPI-2 reporter gene expression is markedly lower in cultured cells that lack endogenous TFPI-2 expression relative to those which retain expression of this gene (Kamei et al., 2001; Konduri et al., 2002; Rao et al., 2003) . Whereas these observations suggest a strong selective pressure to inactivate TFPI-2 in some cancer cells, the data do not exclude the possibility that silencing of this gene occurs simply as a manifestation of altered DNMT activity in these cells (Robertson, 2001) ; furthermore, the data do not exclude the possibility that TFPI-2 expression is governed by other genes that are regulated by DNA methylation. Thus far we have been unable to identify a cell line deficient for TFPI-2 expression in the absence of TFPI-2 promoter methylation, that exhibits induction of TFPI-2 expression following exposure to DNA demethylating agents. These observations, as well as our MSP and bisulfite sequencing data, strongly suggest that methylation events directly targeting the TFPI-2 promoter significantly influence expression of this gene in cancer cells.
Depsipeptide is a potent HDAC inhibitor (Nakajima et al., 1998) , and the results of our ChIP experiments clearly demonstrate that this agent enhances acetylation of core histones, which are associated with the CpG island of the TFPI-2 promoter. In all likelihood, histone acetylation contributes to induction of TFPI-2 expression by DP alone, as well as DP-mediated potentiation of TFPI-2 induction by DAC. Histone acetylation relaxes chromatin, thereby enabling accessibility of transcription factors to recognition sites within promoter regions, and initiation of transcription (Annunziato and Hansen, 2000; Wade, 2001) . Modulation of chromatin structure by HDAC inhibitors has been implicated as a mechanism by which these compounds potentiate induction of tumor suppressor genes in cancer cells by DNA demethylating agents. Interestingly, our data indicate that under exposure conditions known to diminish Erk1/2 signaling in cancer cells (Yu et al., 2002) , DP induces TFPI-2 expression via modulation of PKC signaling. Apicidin induces p21 expression by PKC pathways, which are mediated via SP-1 (Han et al., 2001) ; recent experiments from our lab indicate that DP mediates p21 induction in cancer cells by similar mechanisms (Nguyen et al., 2004) . Although our experiments have not directly demonstrated that the effects of PKC signaling on TFPI-2 expression are mediated via SP-1, it is intriguing that the two SP-1 sites believed to mediate induction of TFPI-2 promoter activity by PMA or DAG lie within in the CpG island of the TFPI-2 promoter (Kamei et al., 2001; Konduri et al., 2002) . Conceivably, methylation within or adjacent to these SP-1 sites modulates PKC signaling at the level of the TFPI-2 promoter. This could account, in part, for the supra-additive effects of sequential DAC/DP treatment on TFPI-2 expression in cultured cancer cells. The data do not exclude the possibility that methylation affects binding of other transcription factors to the TFPI-2 promoter. Experiments are presently underway to examine these issues.
Whereas the mechanisms regulating TFPI-2 expression in cancer cells have not been fully defined, data presented in this manuscript clearly indicate that sequential DAC/DP treatment mediates induction of this target gene. To date, we have not identified a cell line in which TFPI-2 expression is not enhanced following DAC/DP exposure. As such, sequential DAC/ DP treatment may be an effective strategy to restore TFPI-2 expression in primary cancers irrespective of the epigenetic mechanisms by which this gene has been silenced. These observations, together with our MSP results, suggest that TFPI-2 induction may be a useful translational end point for clinical trials evaluating sequential DAC/DP infusion in thoracic oncology patients. Collectively, these data support further analysis of TFPI-2 in thoracic malignancies.
Materials and methods

Drugs and chemicals
DAC was purchased from Sigma, Inc. (St Louis, MO, USA). DP was obtained from the Developmental Therapeutics Program, National Cancer Institute (Bethesda, MD, USA). Cyt3-dUTP and Cyt5-dUTP were purchased from Amersham, Inc. (Buckinghamshire, England). Calphostin and PDBU were purchased from Calbiochem (LaJolla, CA, USA).
Cell lines and drug treatment regimens
All cancer lines were obtained from tissue culture banks at the National Cancer Institute. Normal fibroblasts were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). Cancer lines and normal fibroblasts were maintained in RPMI with 10% fetal calf serum, and were confirmed to be free of mycoplasma contamination. Normal human bronchial epithelial (NHBE) cells were obtained from Cambrex (East Rutherford, NJ, USA), and were cultured as per vendor's recommendations. Trypan blue exclusion techniques were used to evaluate proliferation of lung cancer cells exposed to DAC, DP or sequential DAC/DP.
For RT-PCR, quantitative RT-PCR, Northern blot, and IHC analysis of TFPI-2 expression following drug manipulation, cancer cells (1 Â 10 6 cells/10 cm 2 dish) were exposed either to NM Â 96 h; DAC (0.1 mM) Â 72 h followed by NM Â 24 h; NM Â 72 h, followed by DP (25 ng/ml) Â 6 h, then NM Â 18 h; 0 ACG GAG AAG TAG GGC CA 3 0 (reverse) and techniques similar to those previously described (Weiser et al., 2001a) . The Taqman probe 5 0 CTC CTG CCC CTA GAC TAC GGA CCC TG 3 0 , labeled at the 5 0 end with the reporter dye molecule FAM (6-carboxyfluoroscein) and at the 3 0 end with the quencher dye molecule TAMRA (6-carboxytetramethylrhodamine) was purchased from PE Biosystems Oligonucleotide Factory (Foster City, CA, USA).
For Northern hybridization experiments, a probe for TFPI-2 was generated by RT-PCR, gel purified, and radiolabeled with [ 32 P]d-adenosine triphosphate([ 32 P]d-ATP) by random primer techniques. Total RNA from CALU-6 lung cancer cells was resolved by electrophoresis through 1% agarose formaldehyde gels (20 mg total RNA per lane). The gels were denatured and then neutralized, following which RNA samples were blotted overnight onto magna charged nylon membranes (Micron Separations, Inc., Westboro, MA, USA) through capillary transfer in 20 Â saline sodium citrate (SSC) buffer. Subsequently, the membranes were hybridized with the 32 P-labeled denatured TFPI-2 probe in Hybrizol I solution (Intergen, Purchase, NY, USA) overnight at 451C, and washed as described (Yu et al., 2002) ; bound radioactivity was detected by exposing the blots to X-ray films for 2 h at À701C.
Bisulfite sequencing of the TFPI-2 promoter
The published sequence of the TFPI-2 promoter was analysed using the CpG Software Website (www.ebi.ac.uk/emboss/ cpgplot/index.html). Genomic DNA from cultured cells was subjected to bisulfite modification as described (Herman et al., 1996) , and a 367 bp sequence of the TFPI-2 gene (À342 to þ 25) containing a 275 bp region which fulfilled criteria for CpG island was amplified by PCR techniques using the primer sequences 5 0 GGA TTA TAG GAG AAA GTT TGG GAG G 3 0 (forward), and 5 0 ATA CCT ATT AAC TCC TAA ACA AC 3 0 (reverse), AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA), and the following thermal cycle parameters: (denaturation at 941C for 45 s, annealing at 601C for 1 min, and elongation at 721C for 1 min) Â 40 cycles. PCR fragments were ligated into the PCR 2.1 topo-cloning vector (Invitrogen). Following transformation, plasmids from individual bacterial colonies were isolated, and the TFPI-2 promoter fragments were sequenced using an ABI 310 prism apparatus (Applied Biosystems, Carlsbad, CA, USA), and protocols contained in the topo-cloning kit.
MSP
The CpG software from Serologicals (Norcross, CA, USA) was utilized to design primers that would amplify a 119 bp sequence within the CpG island of the TFPI-2 promoter that would be susceptible to methylation changes. MSP was performed using bisulfite-modified genomic DNA, AmpliTaq gold polymerase, and the following thermal cycle parameters: 941C Â 12 min, (951C Â 2 min, 651C Â 2 min, 721C Â 2 min) Â 4 cycles, (951C Â 10 s, 621C Â 45 s, 721C Â 30 s) Â 40 cycles, followed by extension at 721C for 30 min. PCR primers included: 5 0 TTA CAC AAT TTA CAA CAC AAA AAC AAC AAA A 3 0 (unmethylated forward), 5 0 TTT TGT TTT AGG TGG TTT GGG TGT TTG T 3 0 (unmethylated reverse), 5 0 CAC AAT TTA CAA CGC GAA AAC GAC GAA A 3 0 (methylated foward), and 5 0 TCT TTT AGG CGG TTC GGG TGT TCG T 3 0 (methylated reverse). PCR products were visualized by 3% agarose ethidium bromide gel electrophoresis.
ChIP assay
CALU-6 cells were plated at a density of 2 Â 10 6 cells/10 cm 2 dish and incubated overnight. The next day, cells were exposed to normal media with 0 or 25 ng/ml DP for 6 or 24 h. ChIP was performed as described by Richon et al. (2000) with minor modifications, using murine monoclonal antibodies recognizing acetylated histone H3 and acetylated histone H4 (Upstate Biotechnology, Inc., Lake Placid, NY, USA). The following TFPI-2-specific primers were used to perform PCR from immunoprecipitated DNA as well as input samples: 5 0 ATCTAATCTGAAGGTCCATTGCAAC 3 0 (forward), and 5 0 CTGCAAACTGTGTAAGAGGGAGAG 3 0 (reverse). These primers amplified a 293 bp region overlapping the 5 0 end of the CpG island within the TFPI-2 promoter. The parameters for ChIP-PCR were similar to those used for MSP experiments. PCR products were analysed by 3% agarose ethidium bromide gel electrophoresis.
Western blotting and IHC analysis
For Western blot analysis of histone acetylation following DP exposure, 5 Â 10 6 CALU-6 cells were exposed to NM or DP (25 ng/ml) for 6 or 24 h. Acid-soluble proteins were prepared as described , and quantitated using BCA techniques. Proteins (approximately 20 mg/sample) were denatured and electrophoresed in 15% polyacrylamide gels, followed by immunoblotting with rabbit polyclonal antisera recognizing either acetylated histone H3, or acetylated histone H4. Antibody-labeled histones were detected by enhanced chemiluminescence (ECLt) techniques. Parallel gels were run and stained with Coomassie blue to verify equal protein loading.
For IHC analysis of TFPI-2 expression, 1 Â 10 6 -1 Â 10 7 untreated cancer cells, as well as CALU-6 lung cancer cells exposed to DAC, DP, or sequential DAC/DP, were pelleted into a thrombin-fibrin clot, fixed in formalin, and embedded in paraffin. Tissue sections (4 mM thickness) were blocked with BSA for 1 h at room temperature, followed by 1 h incubation at room temperature with protein A sepharose-purified rabbit polyclonal antisera recognizing TFPI-2 (dilution 1 : 1.000; generously provided by Walter Kisiel, University of New Mexico, Albuquerque, NM, USA). TFPI-2 immunoreactivity was detected by standard immunoperoxidase techniques.
